Drug Trial Radar · NCT00391027
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
261
Actual
Start
Dec 2006
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 23, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin Glargine (Lantus®)Drug
Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
Inhaled Human Insulin (Exubera®)Drug
Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26Time frame: Baseline, Week 26
Locations
62 sites in 10 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Bornem, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Genk, Belgium
Pfizer Investigational Site
Liège, Belgium
Pfizer Investigational Site
Kuopio, Finland
Pfizer Investigational Site
Lahti, Finland
Pfizer Investigational Site
Oulu, Finland
Pfizer Investigational Site
Besançon, France
Pfizer Investigational Site
Corbeil-Essonnes, France
Pfizer Investigational Site
La Rochelle, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Valenciennes, France
Pfizer Investigational Site
Altenburg, Germany
Pfizer Investigational Site
Eisenach, Germany
Pfizer Investigational Site
Hamburg, Germany
Pfizer Investigational Site
Hohenmölsen, Germany
Pfizer Investigational Site
Leipzig, Germany
Pfizer Investigational Site
Neuss, Germany
Pfizer Investigational Site
Riesa, Germany
Pfizer Investigational Site
Wangen / Allgaeu, Germany
Pfizer Investigational Site
's-Hertogenbosch, Netherlands
Pfizer Investigational Site
Eindhoven, Netherlands
Pfizer Investigational Site
Nijmegen, Netherlands
Pfizer Investigational Site
The Hague, Netherlands
Pfizer Investigational Site
Venlo, Netherlands
Pfizer Investigational Site
Bergen, Norway
Pfizer Investigational Site
Jessheim, Norway
Pfizer Investigational Site
Lysaker, Norway
Pfizer Investigational Site
Skedsmokorset, Norway
Pfizer Investigational Site
Hønefoss, Buskerud, Norway
Pfizer Investigational Site
Łask, Poland
Pfizer Investigational Site
Lodz, Poland
Pfizer Investigational Site
Lodz, Poland
Pfizer Investigational Site
Lublin, Poland
Pfizer Investigational Site
Warsaw, Poland
Pfizer Investigational Site
A Coruña, Spain
Pfizer Investigational Site
Huelva, Spain
Pfizer Investigational Site
Málaga, Spain
Pfizer Investigational Site
Valencia, Spain
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.